• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子(VEGF)上调人内皮细胞中内皮型一氧化氮合酶(ecNOS)的信使核糖核酸、蛋白质及一氧化氮(NO)的生成。

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.

作者信息

Hood J D, Meininger C J, Ziche M, Granger H J

机构信息

Microcirculation Research Institute, Texas A&M University Health Science Center, College Station 77843-1114, USA.

出版信息

Am J Physiol. 1998 Mar;274(3):H1054-8. doi: 10.1152/ajpheart.1998.274.3.H1054.

DOI:10.1152/ajpheart.1998.274.3.H1054
PMID:9530221
Abstract

Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that potently stimulates vasodilation, microvascular hyperpermeability, and angiogenesis. Nitric oxide (NO) is also reported to modulate vascular tone, permeability, and capillary growth. Therefore, we hypothesized that VEGF might regulate endothelial production of NO. The production of nitrogen oxides by human umbilical vein endothelial cells (HUVECs) was measured after 1, 12, 24, and 48 h of incubation with VEGF. VEGF treatment resulted in both an acute (1 h) and chronic (> 24 h) stimulation of NO production. Furthermore, Western and Northern blotting revealed a VEGF-elicited, dose-dependent increase in the cellular content of endothelial cell nitric oxide synthase (ecNOS) message and protein that may account for the chronic upregulation of NO production elicited by VEGF. Finally, endothelial cells pretreated with VEGF for 24 h and subsequently exposed to A-23187 for 1 h produced NO at approximately twice the rate of cells that were not pretreated with VEGF. We conclude that VEGF upregulates ecNOS enzyme and elicits a biphasic stimulation of endothelial NO production.

摘要

血管内皮生长因子(VEGF)是一种内皮细胞特异性分泌蛋白,可有效刺激血管舒张、微血管高通透性和血管生成。据报道,一氧化氮(NO)也可调节血管张力、通透性和毛细血管生长。因此,我们推测VEGF可能调节内皮细胞NO的产生。在人脐静脉内皮细胞(HUVECs)与VEGF孵育1、12、24和48小时后,测量其氮氧化物的产生。VEGF处理导致NO产生的急性(1小时)和慢性(>24小时)刺激。此外,蛋白质印迹法和Northern印迹法显示,VEGF引起内皮型一氧化氮合酶(ecNOS)信使和蛋白质的细胞含量呈剂量依赖性增加,这可能解释了VEGF引起的NO产生的慢性上调。最后,用VEGF预处理24小时,随后暴露于A-23187 1小时的内皮细胞产生NO的速率约为未用VEGF预处理的细胞的两倍。我们得出结论,VEGF上调ecNOS酶并引起内皮细胞NO产生的双相刺激。

相似文献

1
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.血管内皮生长因子(VEGF)上调人内皮细胞中内皮型一氧化氮合酶(ecNOS)的信使核糖核酸、蛋白质及一氧化氮(NO)的生成。
Am J Physiol. 1998 Mar;274(3):H1054-8. doi: 10.1152/ajpheart.1998.274.3.H1054.
2
Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability.磷脂酶C、蛋白激酶C和钙在血管内皮生长因子诱导的微静脉高通透性中的作用
Am J Physiol. 1999 Feb;276(2):H535-42. doi: 10.1152/ajpheart.1999.276.2.H535.
3
Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties.血管内皮生长因子对培养的内皮细胞单层转运特性的影响。
Microvasc Res. 2000 Mar;59(2):265-77. doi: 10.1006/mvre.1999.2225.
4
A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells.血管内皮生长因子受体-2(KDR)的一种新功能:在内皮细胞中对血管内皮生长因子A(VEGF-A)刺激作出反应时快速释放一氧化氮。
Biochem Biophys Res Commun. 1999 Nov 30;265(3):636-9. doi: 10.1006/bbrc.1999.1729.
5
Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide.血管内皮生长因子在急性内皮功能障碍期间减弱白细胞与内皮的相互作用:内皮源性一氧化氮的重要作用。
FASEB J. 1999 Jun;13(9):1039-46. doi: 10.1096/fasebj.13.9.1039.
6
Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor.一氧化氮和过氧亚硝酸盐在血管内皮生长因子诱导的视网膜微血管内皮细胞单层通透性变化中的意义
J Vasc Res. 1999 Nov-Dec;36(6):510-5. doi: 10.1159/000025694.
7
Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells.血管内皮生长因子上调内皮细胞中一氧化氮合酶的表达。
Cardiovasc Res. 1999 Mar;41(3):773-80. doi: 10.1016/s0008-6363(98)00228-4.
8
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.血管内皮生长因子受体-1通过一氧化氮调节血管内皮生长因子介导的血管生成。
Am J Pathol. 2001 Sep;159(3):993-1008. doi: 10.1016/S0002-9440(10)61775-0.
9
Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways.血管内皮生长因子(VEGF)介导的内皮细胞一氧化氮(NO)的即时和延迟合成:磷脂酰肌醇-3-激酶(PI3K)、蛋白激酶C(PKC)及磷脂酶C(PLC)信号通路的作用
Br J Pharmacol. 2002 Dec;137(7):1021-30. doi: 10.1038/sj.bjp.0704956.
10
VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways.血管内皮生长因子通过激活蛋白激酶B/蛋白激酶B、内皮型一氧化氮合酶和丝裂原活化蛋白激酶信号通路,增加内皮细胞单层的通透性。
Microvasc Res. 2001 Nov;62(3):252-62. doi: 10.1006/mvre.2001.2338.

引用本文的文献

1
Prevalence and management of hypertension in childhood, adolescent, and young adult cancer survivors: a systematic review and meta-analysis.儿童、青少年和青年癌症幸存者中高血压的患病率及管理:一项系统评价和荟萃分析。
Hypertens Res. 2025 Jul 8. doi: 10.1038/s41440-025-02276-y.
2
Clinicopathological Study on Endothelial Injury in Severe Glomerular Microangiopathy Induced by Ramucirumab.雷莫西尤单抗诱导的严重肾小球微血管病中内皮损伤的临床病理研究
Intern Med. 2025;64(13):2024-2030. doi: 10.2169/internalmedicine.4429-24. Epub 2025 Jul 1.
3
Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia-Focus on the NO System.
产前缺氧后心肌病发展的分子和生化机制——聚焦于一氧化氮系统
Antioxidants (Basel). 2025 Jun 16;14(6):743. doi: 10.3390/antiox14060743.
4
Endothelial dysfunction in chronic kidney disease: a clinical perspective.慢性肾脏病中的内皮功能障碍:临床视角
Am J Physiol Heart Circ Physiol. 2025 Jul 1;329(1):H135-H153. doi: 10.1152/ajpheart.00908.2024. Epub 2025 May 27.
5
Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.健康与疾病中的血管内皮生长因子信号传导:从分子机制到治疗前景
Signal Transduct Target Ther. 2025 May 19;10(1):170. doi: 10.1038/s41392-025-02249-0.
6
Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia.使用一氧化氮调节剂对产前缺氧后内皮功能障碍进行药物纠正的可能性。
Pharmaceuticals (Basel). 2025 Jan 16;18(1):106. doi: 10.3390/ph18010106.
7
Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective study.肝细胞癌患者中乐伐替尼诱导高血压的危险因素:一项回顾性研究。
Br J Clin Pharmacol. 2025 Mar;91(3):894-902. doi: 10.1111/bcp.16337. Epub 2024 Nov 20.
8
Nanoparticle-based approaches for treating restenosis after vascular injury.基于纳米颗粒的血管损伤后再狭窄治疗方法。
Front Pharmacol. 2024 Oct 24;15:1427651. doi: 10.3389/fphar.2024.1427651. eCollection 2024.
9
Nanoparticle delivery of VEGF and SDF-1α as an approach for treatment of pulmonary arterial hypertension.纳米颗粒递送血管内皮生长因子和基质细胞衍生因子-1α作为治疗肺动脉高压的一种方法。
Pulm Circ. 2024 Oct 8;14(4):e12412. doi: 10.1002/pul2.12412. eCollection 2024 Oct.
10
Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.揭示心脏毒性之谜:探索酪氨酸激酶抑制剂治疗的海洋。
Cancer Control. 2024 Jan-Dec;31:10732748241285755. doi: 10.1177/10732748241285755.